European EMA removes about 100 generic drugs
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
European EMA removes about 100 generic drugs involving Johnson & Johnson, Sandoz, Teva, etc.
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
European EMA removes about 100 generic drugs involving Johnson & Johnson, Sandoz, Teva, etc.
A few days ago, the European Medicines Agency (EMA) recommended that European countries suspend the use of about 100 generic drugs.
The European EMA said in a statement that up to 100 generic drugs were recommended to be discontinued this time, mainly because after testing a generic drug from an India-based CRO company, it found that the CRO company’s trial data had integrity problems and even may be suspected of fraud.
The issue has also raised serious concerns about the Indian company’s quality management system and the reliability of data on the company’s website.
Generic companies affected by the European EMA’s decision include Johnson & Johnson, Sandoz, Viatris, Teva, Jubilant, Wockhardt, Accord Healthcare, Aurora Biofarma, Strides Pharma, Tillomed Pharma, Orifarm Generics, Stada, Brillpharma, Micro Labs, ratiopharm , Bennet Pharmaceutica, Medicair Bioscience Laboratories, Pinewood, etc.
It’s worth noting that Synchron Research Services, which is the subject of this outbreak, is not the first CRO company to come under the spotlight for data problems.
Similar problems have occurred with trial data from several Indian CROs, including Semler Research and GVK Biosciences, previously targeted by the US FDA and European EMA.
As was the case with Synchron, regulators also required Semler to repeat the bioequivalence/bioavailability study at an acceptable alternative study site.
And last September, Synchron also came under fire from the FDA for similar data issues.
According to a previous FDA notice to Synchron, the regulator found the company had an abnormal and unexplained record of research that indicated that Synchron engaged in practices and processes that undermined the reliability of analytical methods.
The FDA said, “After careful review of your company’s research records, it was concluded that these practices and processes meant that you submitted falsified research data to the FDA.”
In addition to this, the European and American EMA warned member states that the drugs proposed to be suspended this time “may have crucial effects in certain EU member states”, such as the lack of available alternatives.
Therefore, for the benefit of patients, national authorities can temporarily postpone the decision to suspend the use of the drug.
In addition, Member States should also decide whether the affected drugs need to be recalled within their territories.
Reference source:
Europe to suspend about 100 generic drugs after uncovering data ‘irregularities’ at Indian CRO
European EMA removes about 100 generic drugs involving Johnson & Johnson, Sandoz, Teva, etc.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
